BYOMass is a preclinical pharmaceutical company founded by Margaret Jackson. The company is dedicated to developing innovative biologic and small-molecule drugs that target specific members of the TGF-β superfamily. Their mission is to harness human biology, target causative mechanisms, and deliver novel therapeutics to transform patient lives. BYOMass focuses on addressing both orphan and common diseases with high unmet medical needs.
Notable figures affiliated with BYOMass include its founder, Margaret Jackson. The company has made significant strides in preclinical research, particularly in modulating the TGF-β superfamily for therapeutic purposes. Although still in the preclinical stage, BYOMass has garnered attention for its potential impact on treating diseases that currently lack effective treatments, thereby promising to make a substantial difference in the pharmaceutical landscape.
